

Proteome Sciences plc ("Proteome Sciences" or the "Company")

Annual General Meeting (AGM) Statement

At the Company's AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement:

"Following the delivery of a profit after tax in 2019, we are pleased to report continued progress throughout the business. We have experienced good growth in services revenues and sales of both TMT[®] and TMTpro™ have remained stable over the first 5 months of the year. Despite the challenges of the COVID-19 pandemic, our dedicated staff have ensured we remained fully operational and have delivered 11 projects carried over from 2019 for which we already had samples. A further 10 projects are ongoing and new orders are also being generated. We expect these trends to continue through the rest of the year"

For further information:

Proteome Sciences plc

Dr Ian Pike, Interim Chief Executive Officer & Chief

Scientific Officer Tel: +44 (0)20 7043 2116

Richard Dennis, Chief Commercial Officer

Allenby Capital Limited (AIM Nominated Adviser & Broker)

John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (<u>www.proteomics.com</u>)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibratorTM provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.